These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 29144795

  • 1. RELATIONSHIP BETWEEN THE EFFECTIVENESS OF INORGANIC IODINE AND THE SEVERITY OF GRAVES THYROTOXICOSIS: A RETROSPECTIVE STUDY.
    Honda A, Uchida T, Komiya K, Goto H, Takeno K, Sato J, Suzuki R, Himuro M, Watada H.
    Endocr Pract; 2017 Dec; 23(12):1408-1413. PubMed ID: 29144795
    [Abstract] [Full Text] [Related]

  • 2. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease.
    Takata K, Amino N, Kubota S, Sasaki I, Nishihara E, Kudo T, Ito M, Fukata S, Miyauchi A.
    Clin Endocrinol (Oxf); 2010 Jun; 72(6):845-50. PubMed ID: 19912243
    [Abstract] [Full Text] [Related]

  • 3. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ, Lee BW, Kim JY, Jung JH, Min YK, Lee MS, Lee MK, Kim KW, Chung JH.
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic effectiveness of potassium iodine in drug-naïve patients with Graves' disease: a single-center experience.
    Uchida T, Goto H, Kasai T, Komiya K, Takeno K, Abe H, Shigihara N, Sato J, Honda A, Mita T, Kanazawa A, Fujitani Y, Watada H.
    Endocrine; 2014 Nov; 47(2):506-11. PubMed ID: 24493028
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic efficacy and limitations of potassium iodide for patients newly diagnosed with Graves' disease.
    Suzuki N, Yoshimura Noh J, Sugisawa C, Hoshiyama A, Hiruma M, Kawaguchi A, Morisaki M, Ohye H, Suzuki M, Matsumoto M, Kunii Y, Yoshihara A, Watanabe N, Sugino K, Ito K.
    Endocr J; 2020 Jun 29; 67(6):631-638. PubMed ID: 32188795
    [Abstract] [Full Text] [Related]

  • 6. Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism.
    Sato S, Noh JY, Sato S, Suzuki M, Yasuda S, Matsumoto M, Kunii Y, Mukasa K, Sugino K, Ito K, Nagataki S, Taniyama M.
    Thyroid; 2015 Jan 29; 25(1):43-50. PubMed ID: 25178068
    [Abstract] [Full Text] [Related]

  • 7. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
    Noh JY, Hamada N, Inoue Y, Abe Y, Ito K, Ito K.
    Thyroid; 2000 Sep 29; 10(9):809-13. PubMed ID: 11041459
    [Abstract] [Full Text] [Related]

  • 8. Ratio of serum free triiodothyronine to free thyroxine in Graves' hyperthyroidism and thyrotoxicosis caused by painless thyroiditis.
    Yoshimura Noh J, Momotani N, Fukada S, Ito K, Miyauchi A, Amino N.
    Endocr J; 2005 Oct 29; 52(5):537-42. PubMed ID: 16284430
    [Abstract] [Full Text] [Related]

  • 9. Serum Thyroid Hormone Balance in Levothyroxine Monotherapy-Treated Patients with Atrophic Thyroid After Radioiodine Treatment for Graves' Disease.
    Ito M, Kawasaki M, Danno H, Kohsaka K, Nakamura T, Hisakado M, Yoshioka W, Kasahara T, Kudo T, Nishihara E, Fukata S, Nishikawa M, Nakamura H, Miyauchi A.
    Thyroid; 2019 Oct 29; 29(10):1364-1370. PubMed ID: 31411123
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. POSITIVE THYROTROPIN RECEPTOR ANTIBODIES IN PATIENTS WITH TRANSIENT THYROTOXICOSIS.
    Angell TE, Van Benschoten O, Cohen DA, Haas AV, Alexander EK, Marqusee E.
    Endocr Pract; 2018 Jun 29; 24(6):512-516. PubMed ID: 29624097
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Triiodothyronine-predominant Graves' disease in childhood: detection and therapeutic implications.
    Harvengt J, Boizeau P, Chevenne D, Zenaty D, Paulsen A, Simon D, Guilmin Crepon S, Alberti C, Carel JC, Léger J.
    Eur J Endocrinol; 2015 Jun 29; 172(6):715-23. PubMed ID: 25766047
    [Abstract] [Full Text] [Related]

  • 18. Use of adjunctive potassium iodide after radioactive iodine (131I) treatment of Graves' hyperthyroidism.
    Ross DS, Daniels GH, De Stefano P, Maloof F, Ridgway EC.
    J Clin Endocrinol Metab; 1983 Aug 29; 57(2):250-3. PubMed ID: 6688081
    [Abstract] [Full Text] [Related]

  • 19. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT, Hsieh AT, Pei D, Hung YJ, Wu LY, Yang TC, Lian WC, Huang WS, Kuo SW.
    Clin Endocrinol (Oxf); 2004 Jun 29; 60(6):676-81. PubMed ID: 15163329
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.